Enlicitide for Health & Longevity
Evidence Review created on 11/08/2026 using AI4L + evidence-mcp / GPT 6
Also known as: Enlicitide Decanoate, MK-0616, Lipfendra
Motivation
Enlicitide is an oral prescription medicine designed to influence how the liver removes cholesterol from the bloodstream. It belongs to a developing set of options for people considering how medication might fit into long-term cardiovascular prevention. For adults interested in healthy longevity, its appeal concerns both the biology of cholesterol exposure and the practical demands of a treatment that may be used for many years.
The medicine emerged from efforts to make a cholesterol-targeting approach available without injections. Research has examined daily oral treatment in adults with high cholesterol, including inherited forms, and in people already receiving other cholesterol medicines. These settings raise questions about how closely the evidence applies to adults pursuing prevention before symptoms appear, and about the distinction between laboratory measurements and outcomes that affect length or quality of life.
This review examines enlicitide’s mechanism, clinical evidence, possible harms, dosing conditions, and monitoring. It separates demonstrated treatment effects from indirect evidence and longevity hypotheses, while considering how baseline risk, existing therapy, and daily habits shape interpretation.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
These resources explain the therapeutic category and the principal enlicitide trial.
-
How Nonstatin Drugs Lower Cholesterol - Rhonda Patrick
Explains PCSK9 (proprotein convertase subtilisin/kexin type 9, a protein that limits cholesterol clearance), the target inhibited by enlicitide, alongside other cholesterol treatments. Category context rather than enlicitide-specific outcome evidence.
-
The beginning of the end of atherosclerosis? - Michael Rae, Tom Dayspring & Peter Attia
Places enlicitide within approaches targeting PCSK9, including gene editing. Useful mechanistic context; its description of enlicitide as still in development predates the subsequent approval.
-
Cholesterol Management - Colleen Mazin, Maureen Williams & Debra Gordon
Reviews PCSK9 inhibition alongside nutrition and other treatments. Life Extension sells supplements and laboratory services, creating a commercial interest in its broader discussion; this is context, not evidence of enlicitide outcomes.
-
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. - Navar et al., 2026
The pivotal placebo comparison anchors efficacy and one-year tolerability. Merck/MSD funded this trial and the central development program, with company employees among the investigators; independent replication remains limited.
Four items avoid duplicating expert discussions. No dedicated enlicitide coverage was located from Chris Kresser or Lifespan; the available Huberman discussion repeated Attia’s perspective. Some platforms’ internal searches were incomplete, so absence is not definitive.
Grokipedia
An accessible orientation to the compound and development program. This AI-generated reference is background material; trial publications and the current product label underpin the evidence assessment.
Examine
No enlicitide article was found. Examine primarily covers supplements and nutrition rather than prescription medications.
ConsumerLab
No dedicated enlicitide article could be verified; the site’s search did not return usable results. ConsumerLab primarily evaluates supplements rather than prescription medications.
Systematic Reviews
These enlicitide-specific meta-analyses (statistical combinations of study results) summarize lipid efficacy and safety findings, but largely reuse the same manufacturer-sponsored trials.
-
Efficacy and Safety of Enlicitide in Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. - Farhan et al., 2026
Pools three placebo-controlled trials; distinguishes robust cholesterol effects from exploratory secondary markers and unresolved long-term clinical outcomes.
-
Enlicitide, a Novel Oral Macrocyclic Peptide PCSK9 Inhibitor for Lipid Lowering: A Systematic Review and Meta-Analysis. - Yagmur & Cekirdekci, 2026
Includes four randomized trials and active-comparator evidence; useful breadth, although differences between comparisons and pooled event frequencies complicate safety interpretation.
Mechanism of Action
Enlicitide is a macrocyclic peptide (a small ring-shaped protein fragment) that binds circulating PCSK9. This prevents PCSK9 from directing low-density lipoprotein receptors toward destruction. More receptors remain available on liver cells to remove LDL cholesterol (cholesterol carried in low-density lipoprotein particles) from blood. Discovery experiments showed highly selective binding, supporting a targeted clearance mechanism rather than inhibition of cholesterol production (Johns 2023). Merck financed this work and employed most investigators.
The commercial tablet includes sodium caprate, an absorption enhancer; oral bioavailability (the fraction reaching the circulation) is approximately 1% (Lipfendra label). The effective half-life (the time scale governing accumulation during repeated dosing) is approximately 14 hours (Lipfendra label). The terminal half-life (time for drug levels to halve in the final elimination phase) is approximately 244 hours (Lipfendra label); this long terminal phase does not establish an intermittent dosing regimen. Enlicitide is minimally metabolized, without identified major metabolites, and is primarily eliminated by kidney filtration after intravenous administration (Lipfendra label).
Distribution involves concentration-dependent blood-protein binding; detailed human organ exposure is not established by the label. Its target is outside cells, and the data do not demonstrate direct action on brain aging or cellular rejuvenation. Cholesterol lowering provides a plausible cardiovascular pathway, but neither receptor preservation nor cholesterol lowering alone demonstrates longer survival with enlicitide.
Historical Context & Evolution
Enlicitide was developed for hypercholesterolemia (excess cholesterol in blood), rather than as a general longevity treatment. Its development addressed a delivery problem: blocking PCSK9 had become feasible with injections, while an orally absorbed molecule able to disrupt this protein interaction was harder to produce. Merck’s discovery program combined peptide screening and chemical optimization, then demonstrated target engagement and cholesterol lowering in early human experiments (Johns 2023).
The phase 2 program tested multiple daily doses against placebo and found dose-dependent cholesterol reductions over eight weeks (Ballantyne 2023). Subsequent trials examined longer exposure, inherited high cholesterol, and comparisons with other oral treatments. A one-year placebo-controlled study established sustained lipid efficacy without an apparent overall excess of adverse events (Navar 2026).
The United States subsequently approved Lipfendra for cholesterol lowering alongside diet and exercise in adults, including those with inherited high cholesterol (FDA approval notice). Interest in longevity follows from reducing lifelong exposure to artery-damaging particles and offering an oral route. The evolution is from mechanistic feasibility to demonstrated lipid effects; enlicitide-specific evidence for preventing cardiovascular events or extending life remains a separate question.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High under this review’s independent-research-group criterion: randomized studies belong to a shared Merck-sponsored program with overlapping investigators; independent meta-analyses do not create independent primary experiments.
Medium 🟩 🟩
Lower artery-damaging cholesterol and particle burden
Enlicitide lowers LDL cholesterol through increased receptor-mediated clearance. Phase 2 included participants without background statins (medicines reducing liver cholesterol production) (Ballantyne 2023). CORALreef AddOn enrolled statin-treated adults (Catapano 2026). Related changes in apolipoprotein B (a marker of the number of artery-damaging particles) and non-HDL cholesterol (cholesterol outside high-density lipoproteins) support the same lipid outcome; they are not separate clinical benefits. The sponsor-led evidence does not establish longer life (Navar 2026).
Magnitude: At 24 weeks, the adjusted LDL cholesterol difference versus placebo was −55.8 percentage points, with a 95% CI (confidence interval, the uncertainty range around the estimate) of −60.9 to −50.7 (Navar 2026). In inherited high cholesterol, the corresponding difference was −59.4 percentage points (95% CI −65.6 to −53.2) (Ballantyne 2026). Apolipoprotein B differed by −49.1 percentage points (95% CI −54.0 to −44.3) in that trial (Ballantyne 2026). In the active-comparator trial, LDL cholesterol fell 36.0 percentage points more than with ezetimibe (95% CI 30.2–41.8) (Catapano 2026). The difference versus bempedoic acid plus ezetimibe was 28.1 points (95% CI 22.6–33.6) (Catapano 2026). Secondary markers also changed: lipoprotein(a) (an inherited artery-damaging particle) differed from placebo by −27.5 percentage points (95% CI −34.3 to −20.6) in inherited high cholesterol (Ballantyne 2026). Pooled triglycerides (circulating fats) differed by −13.12 percentage points (95% CI −17.65 to −8.58), an exploratory result driven largely by one trial (Farhan 2026).
Low 🟩
Prevention of cardiovascular events
The human outcome evidence is indirect: injected evolocumab, a different PCSK9 inhibitor, prevented cardiovascular events in an Amgen-funded trial of people with established disease. That supports the target but does not establish enlicitide’s effect or its magnitude in proactive adults without disease (Sabatine 2017).
Magnitude: Not quantified in available studies. No completed enlicitide cardiovascular-outcome trial establishes an event reduction; indirect comparator evidence cannot supply an enlicitide estimate.
Speculative 🟨
Additional benefit from secondary lipid changes
Human trials show lower lipoprotein(a) and triglycerides. Their incremental clinical benefit with enlicitide is unvalidated; speculation concerns clinical benefit, not measured changes (Farhan 2026).
Longer healthspan or lifespan
Less lifetime exposure to artery-damaging particles provides a mechanistic rationale for preserving healthy years. No direct human study establishes enlicitide-mediated lifespan extension, broad functional improvement, or slower biological aging.
Benefit-Modifying Factors
- Baseline lipids: Higher starting concentrations leave more room for absolute cholesterol reduction. Personal significance depends on cumulative exposure and existing disease, not merely percentage laboratory change; long-term absolute event benefit remains unquantified for enlicitide.
- Genetics: Residual LDL receptor function is mechanistically important. Heterozygous familial hypercholesterolemia (inherited high cholesterol from an affected gene copy) responded in a randomized trial; complete receptor deficiency cannot be assumed to respond similarly. No genotype-based dosing algorithm is established (Ballantyne 2026).
- Existing treatment: Phase 3 findings mainly describe additional benefit on established lipid therapy. Comparisons favor enlicitide over tested oral alternatives for cholesterol lowering, but do not establish superiority for cardiovascular outcomes (Catapano 2026).
- Sex: No clinically meaningful sex effect on drug exposure was identified. This does not establish identical lifetime clinical benefit in women and men (Lipfendra label).
- Age: Older adults were represented; no overall effectiveness difference was observed between those aged 65 or older and younger adults. Frailty and competing illness still affect the value of preventive treatment (Lipfendra label).
- Administration: Food can reduce exposure; consistent administration modifies achieved benefit. A human pharmacokinetic study (how the body handles a medicine) supports fasting instructions, while its missed-dose efficacy estimates are model predictions rather than randomized clinical outcomes (Johns 2026).
Potential Risks & Side Effects
High 🟥 🟥 🟥
No harm reaches High: independent research programs have not replicated a specific adverse effect, and available controlled trials do not establish long-term safety.
Medium 🟥 🟥
Diarrhea
A numerical imbalance appeared in the inherited-high-cholesterol trial; its uncertainty interval included no difference. The mechanism was not established, and overall adverse-event rates were similar between groups (Ballantyne 2026). This is a possible tolerability effect, not proof of a consistent causal excess.
Magnitude: Diarrhea occurred in 7.4% versus 2.0% with placebo; the reported difference was 5.4 percentage points (95% CI −0.1 to 10.3) (Ballantyne 2026).
Dizziness
The inherited-high-cholesterol trial showed a numerical imbalance, with uncertainty compatible with no excess (Ballantyne 2026). The regulatory label reports a different frequency; the reason is not established in retrieved material. Dizziness can interfere with training, driving, and balance even when its cause is uncertain.
Magnitude: The publication reports 6.9% versus 4.0%, a difference of 3.0 percentage points (95% CI −3.4 to 8.1) (Ballantyne 2026). The label separately reports 9% versus 4%; these are regulatory figures, not a replacement calculation from the paper (Lipfendra label).
Low 🟥
No additional distinct harm merits Low: pooled randomized evidence found comparable overall adverse events, serious events, and treatment discontinuation, rather than evidence for another causal risk (Farhan 2026).
Speculative 🟨
Fetal or nursing-infant harm
The label raises potential fetal harm through cholesterol lowering, without adequate human pregnancy data. Human milk transfer is unknown (Lipfendra label). Animal developmental studies were reassuring (Lipfendra label); harm remains theoretical.
Rare or delayed adverse effects
One-year trials and limited postmarketing exposure cannot exclude uncommon or delayed harms. No specific chronic neurological, hormonal, or cancer effect is established; these remain unanswered safety questions rather than demonstrated adverse outcomes.
Risk-Modifying Factors
- Genetics: No validated genetic predictor of enlicitide toxicity or actionable pharmacogenetic test was identified. Variants affecting cholesterol clearance concern response more directly than documented side-effect susceptibility.
- Baseline measurements: Very low achieved cholesterol does not itself establish toxicity. Unexpected results or substantial changes from baseline require interpretation with treatment intensity and symptoms; no enlicitide-specific lower stopping threshold is established.
- Sex and reproduction: No clinically meaningful sex difference in exposure was found, but pregnancy introduces a mechanism-based concern. Human pregnancy and lactation safety remain insufficiently characterized (Lipfendra label).
- Kidney and liver disease: Renal impairment raises exposure without a clinically meaningful effect identified in the label. Severe liver impairment, Child-Pugh Class C (advanced liver dysfunction), has not been pharmacokinetically evaluated (Lipfendra label).
- Older age and balance: Trials found no overall age-related safety difference. Dizziness nevertheless has greater practical consequences for people with frailty, falls, or demanding balance-based exercise (Lipfendra label).
Key Interactions & Contraindications
Documented interactions:
- Tested medicines: No clinically meaningful interactions were observed with lithium, levothyroxine, digoxin, warfarin, atorvastatin, alendronate, lisinopril, or oral semaglutide. Separate administration restrictions belonging to those medicines still apply (Lipfendra label).
- Food and beverages: Administration after a meal reduces exposure and may weaken lipid lowering. The label uses an empty stomach and a 30-minute post-dose interval; water, black coffee, and plain tea are permitted (Lipfendra label).
Theoretical interactions (inferred from mechanism, not studied in humans):
- Other PCSK9 treatments: Combining with evolocumab, alirocumab, or inclisiran overlaps the same clearance pathway; incremental benefit and safety are uncertain. This inference supports reviewing duplication rather than assuming additive efficacy.
- Lipid-lowering supplements: Red yeast rice, plant sterols, and soluble fiber could add cholesterol lowering through complementary mechanisms. Magnitude with enlicitide is untested; tracking achieved lipids helps distinguish added effects from unnecessary duplication.
- Over-the-counter binding products: High-dose fiber or intestinal adsorbents could alter absorption, but an enlicitide-specific effect or separation interval is unknown. No established interaction with ordinary nonprescription analgesics was identified.
Populations who should avoid Enlicitide:
- Pregnancy: The label describes discontinuation when pregnancy is recognized unless benefits outweigh fetal risk. This is based on the cholesterol-lowering mechanism and insufficient human data, not demonstrated human birth-defect risk (Lipfendra label).
The label lists no formal contraindications. Breastfeeding involves an individualized benefit–risk assessment, not an absolute prohibition; severe liver disease is an evidence gap rather than a demonstrated contraindication (Lipfendra label).
Risk Mitigation Strategies
Uncited parameters below reflect common clinical practice, not an enlicitide-specific validated protocol.
- Symptom tracking: Recording diarrhea, dizziness, fluid intake, and dose timing during the first month helps identify tolerability problems and alternative causes without presuming every symptom is drug-related.
- Fall prevention: Dizziness during balance-demanding exercise or driving makes those activities unsafe until the symptom resolves; review of other medicines and hydration helps identify compounded causes.
- Reproductive planning: The label’s pregnancy reassessment and discontinuation framework addresses theoretical fetal harm; it does not establish a universal preconception washout interval (Lipfendra label).
- Avoid duplicate doses: The label specifies no two doses on the same day, limiting accidental excess exposure after a missed dose (Lipfendra label).
- Medication reconciliation: Recording prescription drugs, supplements, and existing PCSK9 treatments reduces unstudied duplication and avoids attributing another treatment’s adverse effects to enlicitide.
Therapeutic Protocol
The approved regimen, rather than an established longevity-practitioner regimen, is described below. Uncited operational parameters reflect common practice; no validated enlicitide longevity dose or cycling protocol exists.
- Daily dose: Lipfendra is taken as one 20 mg tablet once daily; split dosing and higher-dose longevity regimens are not established (Lipfendra label).
- Timing: Morning administration on an empty stomach, followed by at least 30 minutes before food or beverages other than water, black coffee, or plain tea, is the labeled regimen (Lipfendra label).
- Formulation: The tablet is swallowed whole, without splitting, crushing, or chewing. Its absorption enhancer is part of the evaluated formulation (Lipfendra label).
- Persistence: Effective half-life is approximately 14 hours, versus a much longer terminal phase. The labeled daily regimen remains the tested approach despite terminal persistence (Lipfendra label).
- Background therapy: CORALreef AddOn tested 20 mg daily enlicitide added to statin therapy, against other oral additions, not a lifestyle-only strategy (Catapano 2026).
- Genetics and starting lipids: No genotype-guided dose has been validated. Baseline lipids and residual receptor function affect rationale and expected response; inherited high cholesterol does not imply a separate approved dose.
- Sex and age: No clinically meaningful exposure effect from sex or age was identified across studied adults aged 18–88. Pediatric effectiveness is not established by this adult regimen (Lipfendra label).
- Organ impairment: Kidney impairment and moderate liver impairment do not imply an established alternative regimen; severe liver impairment was not evaluated. These findings do not establish safety in every severe illness (Lipfendra label).
Discontinuation & Cycling
- Duration: Cholesterol management generally involves continuing exposure while benefit is sought. Enlicitide has not been shown to produce a permanent lipid effect or lasting rejuvenation after discontinuation.
- Withdrawal: No specific withdrawal syndrome or validated taper was identified. Loss of lipid lowering is the expected mechanistic consequence; its individual time course should not be inferred solely from terminal half-life.
- Cycling: Trials and the label use continuous daily treatment. There is no evidence that planned breaks preserve efficacy, prevent tolerance, or improve long-term safety.
- Missed dose: The label permits a missed dose as soon as possible, at least 30 minutes before the next food or restricted drink, without taking two doses that day (Lipfendra label).
Sourcing and Quality
- Evaluated product: Lipfendra is the approved Merck prescription formulation. Its tablet and absorption enhancer cannot be assumed equivalent to bulk enlicitide, compounded capsules, or research peptides (Lipfendra label).
- Quality evidence: Licensed pharmacy supply, intact manufacturer packaging, traceable batch, and expiry date provide more relevant assurance than supplement-style purity claims. A chemical assay alone does not establish oral bioavailability or clinical equivalence.
- Storage: The label specifies the original tightly closed bottle, desiccant retained, and storage at 20–25°C, with permitted excursions to 15–30°C; moisture protection preserves the evaluated product (Lipfendra label).
Practical Considerations
- Time to effect: Near-maximal cholesterol lowering was observed by day 21 in the active-comparator trial and persisted through day 56. This is a laboratory response, not a demonstrated timeline for preventing events (Catapano 2026).
- Common pitfalls: Taking the tablet with breakfast, splitting it, assuming terminal half-life supports weekly dosing, or equating cholesterol change with proven lifespan extension can undermine exposure or interpretation.
- Regulatory scope: United States approval covers adult cholesterol lowering with diet and exercise, including inherited high cholesterol. It is not approval for lifespan extension or evidence of enlicitide-specific cardiovascular-outcome benefit (FDA approval notice).
- Access and cost: Prescription and coverage requirements can impede access; local availability and costs vary. Generic alternatives create a payer incentive to favor cheaper treatments, potentially influencing coverage and guidelines rather than proving biased efficacy findings.
Interaction with Foundational Habits
- Sleep: No direct sleep benefit or disruption is established. A consistent morning routine may indirectly aid adherence, but this is a behavioral inference, not a sleep treatment effect.
- Nutrition: Direct interaction: food alters absorption. The empty-stomach morning dose and 30-minute interval apply regardless of diet; black coffee and plain tea are allowed. Nutritional cholesterol management remains complementary rather than replaced (Lipfendra label).
- Exercise: No direct enhancement or blunting of training adaptation is established. Dizziness could indirectly interrupt exercise or increase fall risk; symptom timing is more relevant than an unvalidated pre-workout dosing strategy.
- Stress management: No direct effect on stress response is established. Reducing missed doses through routines may indirectly improve treatment consistency, but meditation, relaxation, and stress reduction have no demonstrated enlicitide-specific interaction.
Monitoring Protocol & Defining Success
Baseline assessment documents the lipid profile, prior treatment response, existing medicines and supplements, cardiovascular history, and any diarrhea or dizziness already present. Pregnancy or breastfeeding status changes the safety discussion. For an oral treatment whose effect depends on administration, the dosing routine is part of the baseline record rather than a minor detail.
A practical, nonvalidated follow-up schedule is a lipid assessment at four to eight weeks, after material regimen changes, and every three to six months once stable. Symptoms can be recorded during the first month and revisited at each review. Unexpectedly weak response prompts assessment of adherence, formulation, food timing, and background therapy before assuming biological resistance. Success means sustained lipid response with acceptable daily functioning; it does not demonstrate slower aging or a personal survival gain.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| LDL cholesterol | No established target for enlicitide longevity use; track baseline change and individualized clinical goals | Expected treatment response | No universal functional or reference range applies across risk states. Consistent sampling conditions aid comparison; fasting helps when triglycerides are high. |
| Apolipoprotein B | No established target for enlicitide longevity use; track change from baseline | Expected particle-burden response | Complements cholesterol measurement when particle number and cholesterol disagree; use the same laboratory method. |
| Non-HDL cholesterol | No established target for enlicitide longevity use; track change from baseline | Expected lipid response | Calculated in the lipid panel; useful when fasting conditions differ. |
| Lipoprotein(a) | No established enlicitide target; track baseline and change if elevated | Expected secondary marker response | Keep assay and units consistent. Change does not establish independent clinical benefit; frequent repetition is unnecessary for primary response assessment. |
- Tolerability: Stool changes, dizziness, balance, and ability to exercise distinguish acceptable treatment from disruption of daily function.
- Adherence: Dosing, food timing, and missed doses help interpret unexpectedly small laboratory responses.
- Symptoms versus prevention: Better energy, sleep, or cognition is not an established efficacy endpoint; their absence does not establish treatment failure.
Emerging Research
- Cardiovascular events: CORALreef Outcomes, NCT06008756, is an active, nonrecruiting phase 3 placebo comparison with 14,550 planned participants and an event-based primary endpoint; primary completion is estimated November 2029. A positive result would support direct clinical benefit; a null result would weaken extrapolation from cholesterol lowering.
- Longer safety exposure: CORALreef Extension, NCT06492291, is an active phase 3 open-label study with 3,000 planned participants and adverse-event endpoints through approximately three years, completing in 2028. Reassuring findings would expand exposure experience; new harms would narrow the benefit–risk case. No randomized control limits causal reassurance.
- Combined particle targeting: NCT07614984 is a recruiting phase 2 study of MK-7262 with enlicitide, planning 750 participants and measuring lipid changes and safety; completion is estimated October 2027. Positive results could support combined biochemical effects; null or adverse findings would weaken that combination’s rationale, without settling lifespan benefit.
- Rosuvastatin coadministration: NCT07216482 enrolled 996 adults in phase 3. Its November 5, 2026 estimated completion has passed; the record still says active, not recruiting, without posted results. Positive cholesterol findings would support the combination; null results would limit extrapolation. It is not presented as confirmed ongoing.
- Administration flexibility: Human food studies and exposure models suggest resilience to occasional deviations, but modeled efficacy is not an outcomes trial. Confirmation could reduce practical burden; weaker real-world persistence could reduce expected effectiveness (Johns 2026).
Conclusion
Enlicitide offers an oral approach to increasing the liver’s clearance of cholesterol-carrying particles. Its strongest evidence concerns substantial cholesterol lowering, including when existing medication leaves considerable residual exposure. This is relevant to proactive adults whose prevention goals remain difficult to achieve despite sustained attention to diet, exercise, and established treatments. Oral administration changes the practical options, but does not itself establish better adherence or longer life.
The clinical evidence comes mainly from a Merck-sponsored program with overlapping investigators. The consistency of lipid results is persuasive within that program; it is distinct from independent confirmation of long-term benefit. Evidence that another treatment acting on the same target prevents cardiovascular events supports a rationale, while enlicitide-specific event prevention and lifespan extension remain unproven.
Overall short-term tolerability was similar to placebo. Diarrhea and dizziness remain possible practical burdens, and pregnancy introduces a theoretical concern. Rare or delayed harms are not well characterized. The evaluated formulation, daily administration, and relationship to food materially affect how the evidence translates into use. For longevity-oriented adults, the present case rests on sustained management of a measurable cardiovascular risk factor, with its strength depending on baseline exposure, achieved response, and tolerability rather than a demonstrated general rejuvenation effect.